glp 1 drugs novo nordisk EMA will monitor suicide risk in Nordisk's GLP-1 products Ozempic maker Novo Nordisk is

The FDA approval of Wegovy pill is based on the results from the OASIS 4 Phase 3 clinical trial, which was a 64-week medical study that included 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes

Conclusion The clinical and research data accumulated up to July 2026 confirms that GLP-1 receptor agonists possess a highly favorable safety and tolerability profile, especially when weighed against the profound metabolic and cardiovascular benefits they offer

Your primary care provider or a specialist can help you weigh the pros and cons of GLP-1s

Keywords: type 2 diabetes, obesity, glucagon-like peptide-1 receptor agonists, gastrointestinal adverse events, guidelines 1